Akèy › Kansè Endomèt › Texas › San Antonio
Etid klinik pou Kansè Endomèt nan San Antonio, TX
27 etid pou Kansè Endomèt ap chèche patisipan nan sit nan ak bò kote San Antonio (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Ap rekriteFaz 3
- Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- START Center for Cancer Research, San Antonio
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- The University of Texas Health Science Center at San Antonio, San Antonio
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- START - San Antonio, San Antonio
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Ap rekriteFaz 3
- USOR - TX Oncology - SA NE, San Antonio
- NEXT San Antonio, San Antonio
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Ap rekriteFaz 3
- Research Site, San Antonio
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Ap rekriteFaz 1
- NEXT San Antonio, San Antonio
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ap rekriteFaz 1
- Normunity Investigational Site, San Antonio
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- START Center for Cancer Research - San Antonio, San Antonio
- University of Texas (UT) Health, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- UT Health Mays Cancer Center, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- START - San Antonio, San Antonio
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Texas Oncology - San Antonio, San Antonio
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Ap rekriteFaz 3
- Texas Oncology San Antonio Medical Center, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT San Antonio, San Antonio
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- START San Antonio, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Ap rekriteFaz 1
- NEXT Oncology, San Antonio
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- START, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Ap rekriteFaz 2
- START San Antonio, San Antonio
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, San Antonio
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Ap rekriteFaz 2/3
- Texas Oncology-San Antonio Medical Center, San Antonio
Etid Kansè Endomèt nan lòt vil
- Houston, TX68 etid
- New York City, NY52 etid
- Boston, MA50 etid
- Arlington, VA39 etid
- Nashville, TN38 etid
- Los Angeles, CA34 etid
- St. Louis, MO29 etid
- Philadelphia, PA28 etid
- Chicago, IL25 etid
- Columbus, OH25 etid
- Queens, NY25 etid
- Oklahoma City, OK25 etid
Lòt etid nan San Antonio
- Kansè Poumon ki pa ti selil59 etid
- Kansè kolorektal46 etid
- Kansè nan tete46 etid
- Kansè Metastatik44 etid
- Kansè (tout kalite)41 etid
- Obèsite40 etid
- Dyabèt Tip 237 etid
- Sipwa34 etid
- Kansè ovè31 etid
- Kansè pankreyas31 etid
- Kansè pwostat28 etid
- Kansè poumon26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.